COUR Pharmaceuticals

#Autoimmune disease #Biologics / Biotechnology #COUR Pharmaceuticals #Financing #Investment

$105 million raised to support therapies for autoimmune diseases

COUR Pharmaceuticals has secured $105 million in a Series A investment round co-led by Lumira Ventures and Alpha Wave Ventures. The funds will be used to support the advancement of COUR’s myasthenia gravis (MG) and type 1 diabetes (T1D) product candidates into Phase IIa clinical trials. The Roche Venture Fund,… Read More

#Business & Investment #News